Accessibility Menu
Fennec Pharmaceuticals logo

Fennec Pharmaceuticals(NASDAQ) FENC

Market Cap$410.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-90%
5 Year+47%
1 Year+35%
1 Month+17%
Premium Feature
Moneyball Superscore
59/100
$12.07
+3.07%
+0.36Today
Fennec Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 11.712026-08-25
Fennec Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.35%USD 11.872026-08-18
1 month+17.22%USD 9.992026-07-24
3 month+17.45%USD 9.972026-05-27
Year to date+52.08%USD 7.702025-12-31
1 year+35.38%USD 8.652025-08-25
3 year+42.8%USD 8.202023-08-25
5 year+46.93%USD 7.972021-08-26
Since inception-89.67%USD 113.402004-11-12

Fennec Pharmaceuticals Financials at a Glance

Market Cap

$410.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$59.22M

Net Income (TTM)

-$3.25M

EPS (TTM)

-$0.13

P/E Ratio

-91.41

Dividend

$0.00

Beta (Volatility)

0.66 (Low)

Price

$12.07

Volume

103,433.965

Open

$11.70

Previous Close

$11.71

Daily Range

$11.30 - $12.07

52-Week Range

$5.65 - $13.25

Estimated Earnings Date

Nov 12, 2026

FENC News

featured-earnings-leadership-highlights.png

Fennec Q2 Sales Jump 33 Percent

Motley Fool Markets TeamAug 14, 2025

FENC: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. helps children protect their hearing during chemotherapy. Their medicine protects young patients from damage caused by chemotherapy. This drug is used for kids with specific types of tumors.

Protecting Young Ears

  • PEDMARK: Injection used to reduce hearing loss from chemotherapy in children; generated $17.2 million in product sales in the three-month period ended June 30, 2026.
  • PEDMARQSI: Branded name for the same medication sold in European and British markets for pediatric cancer patients.
  • Fennec HEARS: Support program that provides families with financial assistance and help navigating insurance coverage for treatments.

Reaching More Patients

  • Entered an exclusive licensing agreement with Norgine in March 2024 to commercialize its drug in Europe, Australia, and New Zealand.
  • Settled patent litigation with Cipla on March 16, 2026, to resolve claims regarding a generic version of its medicine in the U.S.
  • Launched its primary product in Germany and the U.K. during 2025 through its commercial partnership with Norgine.
  • Announced positive clinical trial results in December 2025 from a study evaluating the drug in patients in Japan.

What Makes Fennec Unique

Fennec holds the only regulatory approval for a therapy designed to prevent hearing loss caused by chemotherapy in children. The company maintains market exclusivity through specialized orphan drug status and a patent portfolio that extends until 2039.

The Recent Financial Turn

  • Total revenue was $17.9 million in the three-month period ended June 30, 2026.
  • Net income reached $2.0 million in the three-month period ended June 30, 2026.
  • Selling and marketing expenses were $10.7 million in the three-month period ended June 30, 2026.
  • Cash and equivalents totaled $41.2 million as of June 30, 2026.

Bottom Line

Fennec has transitioned from a development-stage company into a profitable commercial business with a global licensing network. Its specialized focus on preventing side effects in pediatric oncology has established a unique position in the pharmaceutical market.

AI Generated • Aug 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

35

CEO

Jeffrey S Hackman

Website

www.fennecpharma.com

Headquarters

Research Triangle Park, NC 27709, US

FENC Financials

Key Financial Metrics (TTM)

Gross Margin

93.73%

Operating Margin

-1.96%

Net Income Margin

-5.49%

Return on Equity

-11.71%

Return on Capital

-18.10%

Return on Assets

-4.29%

Earnings Yield

-1.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$410.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

35.07M

Volume

103.43K

Avg. Volume

236.32K

Financials (TTM)

Gross Profit

$55.51M

Operating Income

-$1.16M

EBITDA

-$2.38M

Operating Cash Flow

-$2.04M

Capital Expenditure

$0.00

Free Cash Flow

-$2.04M

Cash & ST Invst.

$41.25M

Total Debt

$0.00

Fennec Pharmaceuticals Performance Analysis

Fennec Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,535,000N/A
20232023-12-31USD 21,252,0001284.5%
20242024-12-31USD 47,538,000123.7%
20252025-12-31USD 44,642,000-6.1%
Fennec Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3029.1%
Q42025-12-3110.6%
Q12026-03-319.7%
Q22026-06-3018.3%
Fennec Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.9035.3%
20232023-12-31USD -0.60-33.1%
20242024-12-31USD -0.02-97.4%
20252025-12-31USD -0.342030.6%
Fennec Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3080.9%
Q42025-12-31-642.4%
Q12026-03-31103.3%
Q22026-06-30792.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$17.87M

+85.2%

Gross Profit

$17.15M

+97.5%

Gross Margin

95.97%

N/A

Market Cap

$410.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.73M

N/A

Employees

35

N/A

Net Income

$1.97M

+162.6%

EBITDA

$1.76M

+169.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$41.25M

+120.5%

Total Debt

$0.00

-100.0%

Accounts Receivable

$23.27M

+32.9%

Inventory

$2.37M

+7.9%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-4.29%

N/A

Return on Invested Capital

-1.84%

N/A

Free Cash Flow

$50.00K

+101.4%

Operating Cash Flow

$50.00K

+101.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTAEnanta Pharmaceuticals, Inc.
$14.25+1.21%
PRLDPrelude Therapeutics Incorporated
$6.55-0.60%
OBIOOrchestra BioMed Holdings, Inc.
$5.33-0.53%
RNACCartesian Therapeutics, Inc.
$10.22-1.54%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$10.60-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.91-0.02%
CRECre8 Enterprise
$6.25+1.43%
NVDANvidia
$209.93-0.01%

Questions About FENC

What is the current price of Fennec Pharmaceuticals?

Fennec Pharmaceuticals is trading at $12.07 per share.

What is the 52-week range for Fennec Pharmaceuticals?

Over the past 52 weeks, Fennec Pharmaceuticals has traded between $5.65 and $13.25.

How much debt does Fennec Pharmaceuticals have?

As of the most recent reporting period, Fennec Pharmaceuticals reported total debt of $0.00.

How much cash does Fennec Pharmaceuticals have on hand?

Fennec Pharmaceuticals reported $41.25M in cash and cash equivalents in its most recent financial results.

What is Fennec Pharmaceuticals’s dividend yield?

Fennec Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services